Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treating type 2 diabetes. euglycemic diabetic ketoacidosis. **Hemodynamically unpredictable thought as atrial fibrillation, orthostatic hypotension or blood circulation pressure lability, prior syncope, etc. ***Clinical scenario described by congestive center failing, edema, renal function Conclusions SGLT2 inhibitors are an appealing novel therapeutic choice … [Read more…]